These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 39033300)

  • 1. Safety and pharmacokinetics of subcutaneous administration of broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs), given to HIV-1 exposed, uninfected neonates and infants: study protocol for a phase I trial.
    Goga A; Ramraj T; Naidoo L; Daniels B; Matlou M; Chetty T; Dassaye R; Ngandu NK; Galli L; Reddy T; Seocharan I; Ndlangamandla Q; September Q; Ngcobo N; Reddy M; Cafun-Naidoo T; Woeber K; Jeenarain N; Imamdin R; Maharajh K; Ramjeth A; Bhengu T; Clarence E; Van de Perre P; Tylleskär T; Nagot N; Moles JP; Moore PL; Mkhize NN; Gama L; Dispinseri S; Biswas P; Scarlatti G;
    BMC Infect Dis; 2024 Jul; 24(1):712. PubMed ID: 39033300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants.
    Cunningham CK; McFarland EJ; Morrison RL; Capparelli EV; Safrit JT; Mofenson LM; Mathieson B; Valentine ME; Perlowski C; Smith B; Hazra R; Purdue L; Muresan P; Harding PA; Mbengeranwa T; Robinson LG; Wiznia A; Theron G; Lin B; Bailer RT; Mascola JR; Graham BS;
    J Infect Dis; 2020 Jul; 222(4):628-636. PubMed ID: 31681963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial.
    Mahomed S; Garrett N; Potloane D; Sikazwe IT; Capparelli E; Harkoo I; Gengiah TN; Zuma NY; Osman F; Mansoor L; Archary D; Myeni N; Radebe P; Samsunder N; Doria-Rose N; Carlton K; Gama L; Koup RA; Narpala S; Serebryannyy L; Moore P; Williamson C; Pozzetto B; Hankins C; Morris L; Karim QA; Abdool Karim S
    BMJ Open; 2023 Aug; 13(8):e076843. PubMed ID: 37640457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial.
    Mahomed S; Garrett N; Karim QA; Zuma NY; Capparelli E; Baxter C; Gengiah T; Archary D; Samsunder N; Doria-Rose N; Moore P; Williamson C; Barouch DH; Fast PE; Pozzetto B; Hankins C; Carlton K; Ledgerwood J; Morris L; Mascola J; Abdool Karim S
    BMJ Open; 2020 Nov; 10(11):e042247. PubMed ID: 33243815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial.
    Walsh SR; Gay CL; Karuna ST; Hyrien O; Skalland T; Mayer KH; Sobieszczyk ME; Baden LR; Goepfert PA; Del Rio C; Pantaleo G; Andrew P; Karg C; He Z; Lu H; Paez CA; Baumblatt JAG; Polakowski LL; Chege W; Anderson MA; Janto S; Han X; Huang Y; Dumond J; Ackerman ME; McDermott AB; Flach B; Piwowar-Manning E; Seaton K; Tomaras GD; Montefiori DC; Gama L; Mascola JR;
    PLoS Med; 2024 Jun; 21(6):e1004329. PubMed ID: 38913710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial.
    Mahomed S; Garrett N; Capparelli E; Baxter C; Zuma NY; Gengiah T; Archary D; Moore P; Samsunder N; Barouch DH; Mascola J; Ledgerwood J; Morris L; Abdool Karim S
    BMJ Open; 2019 Jul; 9(7):e030283. PubMed ID: 31272988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants.
    McFarland EJ; Cunningham CK; Muresan P; Capparelli EV; Perlowski C; Morgan P; Smith B; Hazra R; Purdue L; Harding PA; Theron G; Mujuru H; Agwu A; Purswani M; Rathore MH; Flach B; Taylor A; Lin BC; McDermott AB; Mascola JR; Graham BS;
    J Infect Dis; 2021 Dec; 224(11):1916-1924. PubMed ID: 34009371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial.
    Sobieszczyk ME; Mannheimer S; Paez CA; Yu C; Gamble T; Theodore DA; Chege W; Yacovone M; Hanscom B; Heptinstall J; Seaton KE; Zhang L; Miner MD; Eaton A; Weiner JA; Mayer K; Kalams S; Stephenson K; Julg B; Caskey M; Nussenzweig M; Gama L; Barouch DH; Ackerman ME; Tomaras GD; Huang Y; Montefiori D;
    Lancet HIV; 2023 Oct; 10(10):e653-e662. PubMed ID: 37802566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of broadly neutralizing antibody prophylaxis for HIV-exposed infants in sub-Saharan African settings.
    Dugdale CM; Ufio O; Alba C; Permar SR; Stranix-Chibanda L; Cunningham CK; Fouda GG; Myer L; Weinstein MC; Leroy V; McFarland EJ; Freedberg KA; Ciaranello AL
    J Int AIDS Soc; 2023 Jan; 26(1):e26052. PubMed ID: 36604316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial.
    Mahomed S; Garrett N; Capparelli EV; Osman F; Mkhize NN; Harkoo I; Gengiah TN; Mansoor LE; Baxter C; Archary D; Yende-Zuma N; Samsunder N; Carlton K; Narpala S; McDermott AB; Doria-Rose NA; Moore PL; Morris L; Abdool Karim Q; Mascola JR; Abdool Karim SS
    Lancet HIV; 2023 Apr; 10(4):e230-e243. PubMed ID: 37001964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.
    Mayer KH; Seaton KE; Huang Y; Grunenberg N; Isaacs A; Allen M; Ledgerwood JE; Frank I; Sobieszczyk ME; Baden LR; Rodriguez B; Van Tieu H; Tomaras GD; Deal A; Goodman D; Bailer RT; Ferrari G; Jensen R; Hural J; Graham BS; Mascola JR; Corey L; Montefiori DC; ;
    PLoS Med; 2017 Nov; 14(11):e1002435. PubMed ID: 29136037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial.
    Nagot N; Kankasa C; Tumwine JK; Meda N; Hofmeyr GJ; Vallo R; Mwiya M; Kwagala M; Traore H; Sunday A; Singata M; Siuluta C; Some E; Rutagwera D; Neboua D; Ndeezi G; Jackson D; Maréchal V; Neveu D; Engebretsen IMS; Lombard C; Blanche S; Sommerfelt H; Rekacewicz C; Tylleskär T; Van de Perre P;
    Lancet; 2016 Feb; 387(10018):566-573. PubMed ID: 26603917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial.
    Gaudinski MR; Houser KV; Doria-Rose NA; Chen GL; Rothwell RSS; Berkowitz N; Costner P; Holman LA; Gordon IJ; Hendel CS; Kaltovich F; Conan-Cibotti M; Gomez Lorenzo M; Carter C; Sitar S; Carlton K; Gall J; Laurencot C; Lin BC; Bailer RT; McDermott AB; Ko SY; Pegu A; Kwon YD; Kwong PD; Namboodiri AM; Pandey JP; Schwartz R; Arnold F; Hu Z; Zhang L; Huang Y; Koup RA; Capparelli EV; Graham BS; Mascola JR; Ledgerwood JE;
    Lancet HIV; 2019 Oct; 6(10):e667-e679. PubMed ID: 31473167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV trial under scrutiny.
    Wadman M
    Nature; 2013 Jan; 493(7432):279-80. PubMed ID: 23325184
    [No Abstract]   [Full Text] [Related]  

  • 16. Antiretroviral interventions for preventing breast milk transmission of HIV.
    White AB; Mirjahangir JF; Horvath H; Anglemyer A; Read JS
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD011323. PubMed ID: 25280769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.
    Julg B; Stephenson KE; Wagh K; Tan SC; Zash R; Walsh S; Ansel J; Kanjilal D; Nkolola J; Walker-Sperling VEK; Ophel J; Yanosick K; Borducchi EN; Maxfield L; Abbink P; Peter L; Yates NL; Wesley MS; Hassell T; Gelderblom HC; deCamp A; Mayer BT; Sato A; Gerber MW; Giorgi EE; Gama L; Koup RA; Mascola JR; Monczor A; Lupo S; Rolle CP; Arduino R; DeJesus E; Tomaras GD; Seaman MS; Korber B; Barouch DH
    Nat Med; 2022 Jun; 28(6):1288-1296. PubMed ID: 35551291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087).
    Walsh SR; Gay CL; Karuna ST; Hyrien O; Skalland T; Mayer KH; Sobieszczyk ME; Baden LR; Goepfert PA; Del Rio C; Pantaleo G; Andrew P; Karg C; He Z; Lu H; Paez CA; Baumblatt JAG; Polakowski LL; Chege W; Janto S; Han X; Huang Y; Dumond J; Ackerman ME; McDermott AB; Flach B; Piwowar-Manning E; Seaton K; Tomaras GD; Montefiori DC; Gama L; Mascola JR;
    medRxiv; 2024 Jan; ():. PubMed ID: 38260276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS.
    Awan SF; Pegu A; Strom L; Carter CA; Hendel CS; Holman LA; Costner PJ; Trofymenko O; Dyer R; Gordon IJ; Rothwell RSS; Hickman SP; Conan-Cibotti M; Doria-Rose NA; Lin BC; O'Connell S; Narpala SR; Almasri CG; Liu C; Ko S; Kwon YD; Namboodiri AM; Pandey JP; Arnold FJ; Carlton K; Gall JG; Kwong PD; Capparelli EV; Bailer RT; McDermott AB; Chen GL; Koup RA; Mascola JR; Coates EE; Ledgerwood JE; Gaudinski MR;
    JCI Insight; 2024 Apr; 9(7):. PubMed ID: 38587079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maternal but Not Infant Anti-HIV-1 Neutralizing Antibody Response Associates with Enhanced Transmission and Infant Morbidity.
    Ghulam-Smith M; Olson A; White LF; Chasela CS; Ellington SR; Kourtis AP; Jamieson DJ; Tegha G; van der Horst CM; Sagar M
    mBio; 2017 Oct; 8(5):. PubMed ID: 29066544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.